'김갑성' 기자의 전체기사
-
Kyowa Kirin Announces Abstract Presentation at the Europe…
PRINCETON, N.J. and TOKYO, July 29, 2025 -- Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that results of the Phase 3 ROCKET IGNITE trial of rocatinlimab, an investigational therapy targeting the OX40 receptor (OX40R) in patients with moderate-to-severe atopic dermatitis (AD), will be presented at the European Academy of Dermatology and Venereology (EADV) 2025 Annual Meeting to be held in Paris, France from September 17-20, 2025. AD, a chronic, heterogeneous, inflammatory disease characterized by skin redness, pruritus, and pain, is driven by skin barrier disruption and T-c
- 김갑성 기자
- 2025-07-29 20:00
-
Leo Cancer Care Receives FDA 510(k) Clearance for Marie® - A…
MIDDLETON, Wis., July 29, 2025 -- Leo Cancer Care, a leader in upright radiotherapy solutions, today announces that its flagship product, Marie®, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). Marie represents a paradigm shift in the delivery of particle therapy, combining an upright patient positioning system and a CT scanner that reimagines the treatment experience for both patients and clinicians, whilst drastically reducing the size and cost compared to existing particle therapy solutions. "This clearance marks a majo
- 김갑성 기자
- 2025-07-29 19:55
-
알츠하이머 협회 국제 콘퍼런스 2025: 미국 포인터 연구 결과, 다중 위험 요인 대상으로 한…
주요 내용 미국 포인터 연구에서 인지 기능 저하 위험이 있는 고령자를 대상으로 한 두 가지 생활습관 개입이 모두 인지 기능 개선 효과 보여. 특히 지원과 책임감 요소가 더 많은 구조화된 개입이 자율적 개입보다 더 큰 개선 효과 나타내 인지 기능 저하 고위험군 고령자들을 대상으로 한 다영역 생활 방식 개입, 높은 준수율과 안전성을 보이며 시행돼 인지 기능 개선 효과는 연령, 성별, 인종, 심장 건강 상태, APOE-e4 유전자 보유 여부와 관계없이 일관되게 나타나 토론토, 2025년 7월 29일 -- 알츠하이머 협회(Alzheimer's Association)가 실시한 미국 포인터 연구(U.S. Pointer Study) 또는 '위험을 낮추기 위한 생활 습관 개입을 통한 미국의 두뇌 건강 보호 연구(U.S. Study to Protect Brain Health Through Lifestyle Intervention)'에서 2년간 다기관 임상시험을 통해 두 가지 생활 방식 개입을 시험한 결과 두 방법 모두가 인지 기능 저하 위험이 있는 고령자들의 인지 기능을 향상시킨 것으로 나타났다. 다만 구조화된(ST
- 김갑성 기자
- 2025-07-29 19:37
-
ArisGlobal Achieves Strong Global Growth and Continued Inn…
Expanding Impact of LifeSphere® NavaX™ Across the Industry, 27 Go-Lives, and New Global Pharma Adoptions BOSTON, July 29, 2025 -- ArisGlobal, an AI-first technology company and creator of LifeSphere®, today announced significant momentum in the first half of 2025, driven by continued product innovation via LifeSphere® NavaX™, strong new customer acquisition, and rapid global deployments. Operationalizing AI with LifeSphere® NavaX™ArisGlobal now counts seven global pharmaceutical companies leveraging LifeSphere® NavaX™ across safety operations — a clea
- 김갑성 기자
- 2025-07-29 19:21
-
Fapon to Debut Shine mT8000 Open-Access, High Throughp…
CHICAGO, July 29, 2025 -- Fapon, a global leading life sciences company, will debut its Shine mT8000 Fully Automated Clinical Chemistry and Immunoassay System at the ADLM 2025 Annual Scientific Meeting. This launch marks a significant milestone in Fapon's commitment to building an open, intelligent, and high-efficiency diagnostic ecosystem that helps clinical laboratories to enhance efficiency for clinical chemistry and immunoassays. The Shine mT8000 system packs powerful performance into a footprint just 5 square meters, combining biochemistry and immunoassay capabilities in o
- 김갑성 기자
- 2025-07-29 18:00
-
WuXi Biologics Singapore CRDMO Hub Advances with the Lau…
[ 메디채널 김갑성 기자 ] Innovative modular design will accelerate construction and manufacturing timelines, enabling rapid adaptation of manufacturing capacities across diverse product formats. Finished building will be one of the world's largest modular biologics Drug Product (DP) facilities, and will enhance WuXi Biologics' leadership in end-to-end DP capabilities. SINGAPORE, July 29, 2025 -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced construction has begun for a new modular Drug Product (DP) facility, wh
- 김갑성 기자
- 2025-07-29 16:00
-
Tigermed Completes Acquisition of Japanese CRO Micron
HANGZHOU, China and TOKYO, July 29, 2025 -- Tigermed (300347.SZ / 3347.HK), a leading global provider of clinical research solutions across the full lifecycle of global biopharmaceutical and medical device products, today announces the completion of its acquisition of CRO company Micron,Inc. Founded in 2005 and headquartered in Tokyo, Micron is a Japan-based Contract Research Organization (CRO) focusing in medical imaging and clinical trial services with over 160 employees. Micron brings nearly two decades of expertise in clinical research and the largest team of imaging expert
- 김갑성 기자
- 2025-07-29 13:37
-
Alphamab Oncology Announces Anti-HER2 Biparatopic ADC JS…
SUZHOU, China, July 29, 2025 -- Alphamab Oncology (stock code: 9966.HK) announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of gastric cancer and gastroesophageal junction cancer (GC/GEJ). GC/GEJ is the fifth most common cancer and the fifth leading cause of cancer death worldwide. According to the 2022 Global Cancer Statistics report released by the International Agency for Research on Cancer (IARC), a subsidiary of the World Health Organization, there
- 김갑성 기자
- 2025-07-29 10:37
-
Agilent and Nanyang Technological University's NEWRI Sign A…
SINGAPORE, July 29, 2025 -- Agilent Technologies Inc. (NYSE: A) announced the recent signing of a Memorandum of Understanding (MOU) with the Nanyang Environment & Water Research Institute (NEWRI), outlining their collaboration in advancing environmental and water research over the next three years. NEWRI is a leading research institute at Nanyang Technological University, Singapore (NTU Singapore), ranked 13th globally for Environmental Sciences by QS World University Ranking in 2025¹. The collaboration aims to further strengthen Singapore's capabilities in detecting e
- 김갑성 기자
- 2025-07-29 09:00
-
FROM THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2025…
Key Takeaways Two lifestyle interventions in U.S. POINTER improved cognition in older adults at risk of cognitive decline. A structured intervention with more support and accountability showed greater improvement compared to a self-guided intervention. In a large, representative group of older adults at high risk for cognitive decline, multidomain lifestyle interventions were delivered with high adherence and safety. Cognitive benefits were consistent across age, sex, ethnicity, heart health status and apolipoprotein E-e4 genotype. TORONTO, July 29, 2025 -- The
- 김갑성 기자
- 2025-07-29 02:39
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-08-20_WED
- Global Times: Development opportunities, potential and advantages should be better used 23:58
- First IPO Under GIFT City's IFSC Regime - DRHP Filed; Executive Education Platform Leads the Charge 22:19
- Sisram Medical Reports First-Half 2025 Results: Injectables Surge as AI-Powered EBD Strengthens Segment Positioning 22:14
- TGE alongside with AMTD Obtain Successful Court Decisions against Unauthorised and Infringing Activities in Austria 21:55
- Zylox-Tonbridge Announces 2025 Interim Results: Strong Revenue Growth with Net Profit Surging Over 76% Year-over-Year 21:41
- FOSSIL AND 2025-2026 GLOBAL BRAND AMBASSADOR NICK JONAS RELEASE EXCLUSIVE "MACHINE LUXE" CAPSULE 21:00
- IBM and NASA Release Groundbreaking Open-Source AI Model on Hugging Face to Predict Solar Weather and Help Protect Critical Technology 21:00
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 08월 21일 01시 40분